Stock Events

Stock Events

Moleculin Biotech 

$2.79
83
+$0.05+1.82% Today

Statistics

Day High
2.88
Day Low
2.67
52W High
23.78
52W Low
1.96
Volume
113,662
Avg. Volume
-
Mkt Cap
142.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-17.02
-11.26
-5.51
0.25
Expected EPS
-1.543333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-43.53MNet Income

Analyst Ratings

22Average Price Target
The highest estimate is 22.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Moleculin, including cancer, making it a direct competitor.
AMGEN
AMGN
Mkt Cap183.12B
Amgen focuses on human therapeutics, including treatments for cancer, which competes with Moleculin's cancer drug development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Moleculin's oncology focus.
Merck
MRK
Mkt Cap302.33B
Merck operates in the pharmaceutical industry with a strong emphasis on cancer drugs, competing with Moleculin's product pipeline.
Pfizer
PFE
Mkt Cap147.62B
Pfizer is a global biopharmaceutical company with a broad range of drugs, including cancer treatments that compete with Moleculin's developments.
Novartis
NVS
Mkt Cap290.05B
Novartis is a healthcare company that offers treatments for a variety of conditions, including cancer, making it a competitor to Moleculin.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, directly competing with Moleculin's focus areas.
Lilly(Eli) &
LLY
Mkt Cap949.7B
Eli Lilly is a global healthcare leader that develops drugs for cancer among other diseases, positioning it as a competitor to Moleculin.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a significant focus on oncology, competing with Moleculin.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals is known for its innovative medicines and therapeutic advancements, including in oncology, making it a competitor to Moleculin.

About

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Show more...
CEO
Mr. Walter V. Klemp
Employees
17
Country
United States
ISIN
US60855D4088

Listings

F
DE
MOL0.F
MU
DE
MOL0.MU
LSE
GB
0K2H.LSE
BOATS
BOATS
MBRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Moleculin Biotech stock price today?▼
The current price of MBRX is $2.79 USD — it has increased by +1.82% in the past 24 hours. Watch Moleculin Biotech stock price performance more closely on the chart.
What is Moleculin Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Moleculin Biotech stocks are traded under the ticker MBRX.
Is Moleculin Biotech stock price growing?▼
MBRX stock has risen by +16.74% compared to the previous week, the month change is a +11.16% rise, over the last year Moleculin Biotech has showed a -87.71% decrease.
What is Moleculin Biotech market cap?▼
Today Moleculin Biotech has the market capitalization of 142.04M
When is the next Moleculin Biotech earnings date?▼
Moleculin Biotech is going to release the next earnings report on August 19, 2026.
What were Moleculin Biotech earnings last quarter?▼
MBRX earnings for the last quarter are -3.54 USD per share, whereas the estimation was -2.33 USD resulting in a -51.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Moleculin Biotech revenue for the last year?▼
Moleculin Biotech revenue for the last year amounts to 0 USD.
What is Moleculin Biotech net income for the last year?▼
MBRX net income for the last year is -43.53M USD.
How many employees does Moleculin Biotech have?▼
As of May 29, 2026, the company has 17 employees.
In which sector is Moleculin Biotech located?▼
Moleculin Biotech operates in the Health & Wellness sector.
When did Moleculin Biotech complete a stock split?▼
The last stock split for Moleculin Biotech was on December 01, 2025 with a ratio of 1:25.
Where is Moleculin Biotech headquartered?▼
Moleculin Biotech is headquartered in Houston, United States.